Is Thermo Fisher Scientific Inc (TMO) overvalued? · P/E 24, rev $44.56B
Thermo Fisher Scientific Inc (TMO) is a diagnostics & research company listed on US.
This page asks whether Thermo Fisher Scientific Inc (TMO) looks expensive on cached numbers — not a short thesis.
Latest reported TMO revenue for 2025-12-31 was $44.56B. Net income was $6.70B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
TMO currently screens at market cap $153.06B and trailing P/E 23.8. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TMO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TMO stock page for the full model, not this heading.
Not investment advice.